title: MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
abstract: The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
authors: Medical Oncology Unit, San Raffaele H Scientific Institute, Università Vita-Salute San Raffaele, Milan, Italy. ferreri.andres@hsr.it
authors: A J M
authors: AJ
authors: Ferreri
authors: S
authors: S
authors: Dell'Oro
authors: M
authors: M
authors: Foppoli
authors: M
authors: M
authors: Bernardi
authors: A A
authors: AA
authors: Brandes
authors: A
authors: A
authors: Tosoni
authors: M
authors: M
authors: Montanari
authors: M
authors: M
authors: Balzarotti
authors: M
authors: M
authors: Spina
authors: F
authors: F
authors: Ilariucci
authors: F
authors: F
authors: Zaja
authors: C
authors: C
authors: Stelitano
authors: F
authors: F
authors: Bobbio
authors: G
authors: G
authors: Corazzelli
authors: L
authors: L
authors: Baldini
authors: M
authors: M
authors: Ponzoni
authors: P
authors: P
authors: Picozzi
authors: F
authors: F
authors: Caligaris Cappio
authors: M
authors: M
authors: Reni